Albumin‑bound sirolimus plus long‑acting octreotide for metastatic gastroenteropancreatic neuroendocrine tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional Phase II/III program begins with a Phase II safety run‑in and proceeds to later‑phase evaluation of treatment efficacy. The planned regimen pairs albumin‑bound sirolimus with octreotide long‑acting injection, and everolimus is also listed among the interventions. Eligible patients are adults with unresectable or recurrent non‑functional G1/G2 GEP‑NETs with poor prognostic features, ECOG 0–2, and adequate organ function, with at least one RECIST v1.1‑measurable lesion required for the Phase II safety run‑in. The trial is led by CSPC ZhongQi Pharmaceutical Technology and is conducted at Chinese PLA General Hospital in Beijing.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 1\. Unresectable locally advanced or metastatic G1/G2 GEP-NETs diagnosed by histology, according to the 2019 WHO histological grading criteria.
* 2\. Having poor prognostic factors.
* 3\. Non-functional GEP-NETs are required.
* 4\. At least one evaluable lesion meets the RECIST V1.1 standard (Applicable only to the phase II safety run-in stage)
* 6\. ECOG 0\~2.
* 7\. Organ function reserve is good.
* 8\. Be able to sign a written informed consent form.

Exclusion Criteria:

* 1\. Patients who have previously received SSTR-targeted therapies (including somatostatin analogs \[SSAs\] and peptide receptor radionuclide therapy) and/or mTOR inhibitors (Patients who received SSAs in the adjuvant setting and experienced recurrence ≥6 months after treatment completion may be enrolled)\[ Applicable to Phase II dose expansion and Phase III stages\].
* 2\. Has uncontrolled/severe diarrhea or an axillary temperature \> 38.0°C at enrollment.
* 3\. Received treatment with other unlisted clinical investigational drugs within 4 weeks prior to the first use of the investigational drug.
* 4\. Undergone major surgical procedures within 4 weeks prior to the first use of the investigational drug and have not fully recovered.
* 5\. Received systemic use of corticosteroids or other immunosuppressive therapy within 2 weeks prior to the first use of the study drug.
* 6\. With an infection that requires systemic anti-infective treatment within 2 weeks prior to the first use of the study drug.
* 7\. Those who have used strong inhibitors or inducers of CYP3A4 liver metabolic enzymes within 2 weeks prior to the first use of the investigational drug or still need to continue using such drugs.
* 8\. Has a serious history of cardiovascular and cerebrovascular diseases.
* 9\. Having active brain metastasis and/or malignant meningitis.
* 10\. With a history of severe lung diseases.
* 11\. During screening, there may be symptomatic gallstones or a history of symptomatic gallstones but no surgical treatment has been performed.
* 12\. Abnormal thyroid function during screening.
* 13\. Known to have hypersensitivity reactions or intolerance to any component of all investigational drugs or their excipients.
* 14\. Active hepatitis B, active hepatitis C virus infection, or active syphilis infection.
* 15\. History of autoimmune diseases (excluding tuberous sclerosis), history of immunodeficiency, including HIV testing positive, or other acquired or congenital immunodeficiency diseases, or history of organ transplantation.

Where it's running

• Chinese PLA General Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: Clinical Trials Information Group officer
• Email: ctr-contact@cspc.cn
• Phone: 86-0311-69085587

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Delayed Ga-68 DOTATATE PET/MR for Detecting Liver Metastases in GEP-NETs

  This study tests whether a delayed Ga-68 DOTATATE PET/MR scan can better detect liver metastases in gastroenteropancreatic neuroendocrine tumors compared with the standard Ga-68 DOTATATE PET/CT.

  Recruiting First Affiliated Hospital of Fujian Medical University · Fuzhou, Fujian · NCT07898904

• Combination treatment of cabozantinib and lanreotide for advanced gastroenteropancreatic neuroendocrine tumors

  This study is testing a new combination of daily cabozantinib and monthly lanreotide to see if it helps people with advanced gastroenteropancreatic neuroendocrine tumors who haven't responded to previous treatments.

  Recruiting at 11 sites Phase 1/2 National Health Research Institutes, Taiwan · Changhua and 10 other locations · NCT05048901

• GEP-NET treatment patterns and outcomes in the U.S.

  This study will see how newly diagnosed GEP-NET patients are treated in real-world settings and what their outcomes look like.

  Recruiting Novartis · East Hanover, New Jersey · NCT07635316

• Nutritional status monitoring for adults with gastroenteropancreatic neuroendocrine tumors

  This project will see if nutrition problems are common and linked to outcomes in adults aged 18–70 being followed for gastroenteropancreatic neuroendocrine tumors at Strasbourg University Hospital.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07302100

• RYZ401 for solid tumors that express somatostatin receptors

  This trial will try RYZ401, a targeted radiotherapy, in adults with neuroendocrine or other solid tumors that show somatostatin receptors to find a safe dose and see if it shrinks tumors.

  Recruiting at 15 sites Phase 1 RayzeBio, Inc. · Phoenix, Arizona and 14 other locations · NCT07165132

• Characterizing Gastroenteropancreatic Neuroendocrine Tumors Treated With Targeted Radionuclide Therapy

  This study is trying to see if advanced imaging can help doctors choose the right patients for a specific cancer treatment for gastroenteropancreatic neuroendocrine tumors to improve their chances of success.

  Recruiting at 3 sites Assistance Publique - Hôpitaux de Paris · Clichy and 4 other locations · NCT06256705

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.